Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMEC8E2)

• Drug Name: Anle138b Drug Info
• Synonyms: Anle138b; 882697-00-9; Emrusolmin; ANLE-138b; 3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1h-pyrazole; Emrusolmin [INN]; E7WRA77JET; 5-(1,3-benzodioxol-5-yl)-3-(3-bromophenyl)-1H-pyrazole; CHEMBL4748063; 3-(Benzo[d][1,3]dioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole; 1H-Pyrazole, 3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-; Anle 138b; UNII-E7WRA77JET; Anle 138b; Anle-138b; SCHEMBL1660250; SCHEMBL21440048; BCP32558; Anle138b, >=98% (HPLC); BDBM50553260; MFCD30146410; NSC805132; s6782; AKOS037649277; CS-6522; DB13927; NSC-805132; BS-17773; HY-101855; D80685; EN300-331610; A858288; Z2327237898; 3-(1,3-dioxaindan-5-yl)-5-(3-bromophenyl)-1H-pyrazole

Indication

Disease Entry	ICD 11	Status	REF
Parkinson disease	8A00.0	Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 44608289
  TTD Drug ID: DMEC8E2

Molecule-Related Drug Atlas

Drug(s) Targeting Synuclein alpha (SNCA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RG7935	DME1YMX	Parkinson disease	8A00.0	Phase 2	[3]
BIIB054	DMZO2SY	Parkinson disease	8A00.0	Phase 2	[4]
PRX002	DMKTP8E	Parkinson disease	8A00.0	Phase 2	[5]
TAK-341	DM6D30Q	Multiple system atrophy	8D87.0	Phase 2	[6]
MEDI1341	DMQDBSU	Parkinson disease	8A00.0	Phase 1	[4]
Posiphen R-phenserine	DMCU54M	Alzheimer disease	8A20	Phase 1	[7]
NPT200-11	DMFDBV5	Multiple system atrophy	8D87.0	Phase 1	[8]
SAR446159	DMWAO33	Parkinson disease	8A00.0	Phase 1	[9]
UCB7853	DMD7I23	Parkinson disease	8A00.0	Phase 1	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Synuclein alpha (SNCA)	TT08OSU	SYUA_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT04685265) A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of anle138b, and to Characterise the Effect of Food of anle138b in Mild to Moderate Parkinson's Disease. U.S.National Institutes of Health.
• [2] Anle138b interaction in alpha-synuclein aggregates by dynamic nuclear polarization NMR. Methods. 2023 Jun;214:18-27.
• [3] alpha-Synuclein in Parkinson's Disease. Cold Spring Harb Perspect Med. 2012 February; 2(2): a009399.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-alpha-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2018 Oct 1;75(10):1206-1214.
• [6] Preclinical development of a high affinity alpha-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular alpha-synuclein and attenuate alpha-synuclein spreading in vivo. Neurobiol Dis. 2019 Dec;132:104582.
• [7] The Anticholinesterase Phenserine and Its Enantiomer Posiphen as 5 ntranslated-Region-Directed Translation Blockers of the Parkinson's Alpha Synuclein Expression. Parkinson's Disease Volume 2012 (2012), Article ID 142372, Page(13).
• [8] The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease. Sci Rep. 2018 Nov 1;8(1):16165.
• [9] Clinical pipeline report, company report or official report of Sanofi
• [10] ClinicalTrials.gov (NCT04651153) A Multicenter, Participant-Blind, Investigator-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of UCB7853 in Healthy Male Study Participants and Multiple Ascending Doses in Patients With Parkinson's Disease. U.S.National Institutes of Health.